DEOD: uncovering dominant effects of cancer-driver genes based on a partial covariance selection method

MOTIVATION The generation of a large volume of cancer genomes has allowed us to identify disease-related alterations more accurately, which is expected to enhance our understanding regarding the mechanism of cancer development. With genomic alterations detected, one challenge is to pinpoint cancer-driver genes that cause functional abnormalities. RESULTS Here, we propose a method for uncovering the dominant effects of cancer-driver genes (DEOD) based on a partial covariance selection approach. Inspired by a convex optimization technique, it estimates the dominant effects of candidate cancer-driver genes on the expression level changes of their target genes. It constructs a gene network as a directed-weighted graph by integrating DNA copy numbers, single nucleotide mutations and gene expressions from matched tumor samples, and estimates partial covariances between driver genes and their target genes. Then, a scoring function to measure the cancer-driver score for each gene is applied. To test the performance of DEOD, a novel scheme is designed for simulating conditional multivariate normal variables (targets and free genes) given a group of variables (driver genes). When we applied the DEOD method to both the simulated data and breast cancer data, DEOD successfully uncovered driver variables in the simulation data, and identified well-known oncogenes in breast cancer. In addition, two highly ranked genes by DEOD were related to survival time. The copy number amplifications of MYC (8q24.21) and TRPS1 (8q23.3) were closely related to the survival time with P-values = 0.00246 and 0.00092, respectively. The results demonstrate that DEOD can efficiently uncover cancer-driver genes.

[1]  D. Pe’er,et al.  Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data , 2003, Nature Genetics.

[2]  R. Gilbert,et al.  Recurrent genomic alterations in sequential progressive leukoplakia and oral cancer: drivers of oral tumorigenesis? , 2014, Human molecular genetics.

[3]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[4]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[5]  A. Jalota-Badhwar,et al.  Gene regulation by SMAR1: Role in cellular homeostasis and cancer. , 2011, Biochimica et biophysica acta.

[6]  Hyunju Lee,et al.  WMAXC: A Weighted Maximum Clique Method for Identifying Condition-Specific Sub-Network , 2014, PloS one.

[7]  Fan Zhang,et al.  Discovery of pathway biomarkers from coupled proteomics and systems biology methods , 2010, BMC Genomics.

[8]  Y. Taketani,et al.  PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  Dana Pe'er,et al.  JISTIC: Identification of Significant Targets in Cancer , 2010, BMC Bioinformatics.

[10]  D. Pe’er,et al.  An Integrated Approach to Uncover Drivers of Cancer , 2010, Cell.

[11]  D. Bertsekas,et al.  TWO-METRIC PROJECTION METHODS FOR CONSTRAINED OPTIMIZATION* , 1984 .

[12]  Ryan K. Orosco,et al.  Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss , 2014, Nature Genetics.

[13]  Chris Mungall,et al.  AmiGO: online access to ontology and annotation data , 2008, Bioinform..

[14]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .

[15]  P. Parfrey,et al.  Serotonin Transporter Gene (SLC6A4) Variations Are Associated with Poor Survival in Colorectal Cancer Patients , 2012, PloS one.

[16]  K. Black,et al.  Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era , 2012, PloS one.

[17]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[18]  Yan Liu,et al.  A central role for TRPS1 in the control of cell cycle and cancer development , 2014, Oncotarget.

[19]  S. Rafii,et al.  Splitting vessels: Keeping lymph apart from blood , 2003, Nature Medicine.

[20]  Jolanta Lissowska,et al.  TGF-β Signaling Pathway and Breast Cancer Susceptibility , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[21]  P. V. van Diest,et al.  Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer , 2011, The Journal of pathology.

[22]  D. Pe’er,et al.  RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation. , 2013, Cancer research.

[23]  N. Higham.  COMPUTING A NEAREST SYMMETRIC POSITIVE SEMIDEFINITE MATRIX , 1988 .

[24]  Paul A. Bates,et al.  Global topological features of cancer proteins in the human interactome , 2006, Bioinform..

[25]  L. Feng,et al.  Insights into significant pathways and gene interaction networks underlying breast cancer cell line MCF-7 treated with 17β-estradiol (E2). , 2014, Gene.

[26]  Jie Xu,et al.  Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients , 2014, Translational oncology.

[27]  M. Duffy,et al.  p53 as a target for the treatment of cancer. , 2014, Cancer treatment reviews.

[28]  Anne-Marie Cleton-Jansen,et al.  FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex. , 2005, Cancer research.

[29]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..

[30]  Olufunmilayo I Olopade,et al.  MYC in breast tumor progression , 2008, Expert review of anticancer therapy.

[31]  D. Radisky,et al.  MYC Suppresses Cancer Metastasis by Direct Transcriptional Silencing of αv and β3 Integrin Subunits , 2012, Nature Cell Biology.

[32]  B. Győrffy,et al.  A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers , 2014, Molecular oncology.

[33]  M. Katoh,et al.  Comparative genomics on mammalian Fgf3-Fgf4 locus. , 2005, International journal of oncology.

[34]  Rainer König,et al.  The functional cancer map: A systems-level synopsis of genetic deregulation in cancer , 2011, BMC Medical Genomics.

[35]  Natalie Wilson,et al.  Human Protein Reference Database , 2004, Nature Reviews Molecular Cell Biology.

[36]  Olufunmilayo I Olopade,et al.  MYC and Breast Cancer. , 2010, Genes & cancer.

[37]  Wei Keat Lim,et al.  The transcriptional network for mesenchymal transformation of brain tumors , 2009, Nature.

[38]  V. Cormier-Daire,et al.  The ADAMTS(L) family and human genetic disorders. , 2011, Human molecular genetics.

[39]  Richard A. Johnson,et al.  Applied Multivariate Statistical Analysis , 1983 .

[40]  David Haussler,et al.  PARADIGM-SHIFT predicts the function of mutations in multiple cancers using pathway impact analysis , 2012, Bioinform..

[41]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[42]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.